PMID- 38115039
OWN - NLM
STAT- MEDLINE
DCOM- 20231221
LR  - 20231223
IS  - 2047-783X (Electronic)
IS  - 0949-2321 (Print)
IS  - 0949-2321 (Linking)
VI  - 28
IP  - 1
DP  - 2023 Dec 19
TI  - A combined analysis of multi-omics data reveals the prognostic values and 
      immunotherapy response of LAG3 in human cancers.
PG  - 604
LID - 10.1186/s40001-023-01583-9 [doi]
LID - 604
AB  - Lymphocyte-activation gene 3 (LAG3) is a highly anticipated immune checkpoint in 
      the context of cancer, exerting regulatory control over immune cell proliferation 
      and function to reinforce the advancement of cancers. However, the comprehensive 
      functional analysis of LAG3 across various cancer types remains undisclosed; 
      thus, this study aims to investigate the pan-cancer expression profile of LAG3. 
      We have investigated the expression profile, prognostic significance, and genetic 
      alterations of LAG3 in various cancers while elucidating its characteristic in 
      immune response regulation. Our findings demonstrated that elevated LAG3 
      expression is significantly associated with favorable prognosis in patients with 
      cutaneous melanoma (SKCM), and it may be a potential biomarker for SKCM. 
      Furthermore, multiple immune algorithms have highlighted the important regulatory 
      role of LAG3 for the tumor-infiltrating immune cells including CD8 + T cells, B 
      cells, dendritic cells (DCs), macrophages, and natural killer (NK) cells. We also 
      examined the distribution of LAG3 at the single-cell level and explored its 
      functional significance. A comprehensive and systematic analysis of LAG3 would 
      facilitate a comprehensive evaluation of LAG3 in cancer biology and provide 
      valuable insights for cancer management.
CI  - (c) 2023. The Author(s).
FAU - Peng, Jinwu
AU  - Peng J
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      410008, Hunan, China.
AD  - Department of Pathology, Xiangya Changde Hospital, Changde, 415000, Hunan, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, 
      Central South University, Changsha, 410008, Hunan, China.
FAU - Du, Zhihao
AU  - Du Z
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      410008, Hunan, China.
FAU - Sun, Yuwei
AU  - Sun Y
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      410008, Hunan, China.
FAU - Zhou, Zhiyang
AU  - Zhou Z
AD  - Department of Breast Surgery, Xiangya Hospital, Central South University, 
      Changsha, 410008, Hunan, China. zhouzy@csu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20231219
PL  - England
TA  - Eur J Med Res
JT  - European journal of medical research
JID - 9517857
RN  - 0 (Antigens, CD)
RN  - 0 (Lymphocyte Activation Gene 3 Protein)
SB  - IM
MH  - Humans
MH  - Prognosis
MH  - Antigens, CD/metabolism
MH  - *Melanoma/genetics/therapy
MH  - Multiomics
MH  - Lymphocyte Activation Gene 3 Protein
MH  - *Skin Neoplasms/genetics/therapy
MH  - Immunotherapy
PMC - PMC10729452
OTO - NOTNLM
OT  - Cancer
OT  - Expression
OT  - Immune
OT  - Lymphocyte-activation gene 3
OT  - Prognosis
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2023/12/20 06:42
MHDA- 2023/12/21 06:42
PMCR- 2023/12/19
CRDT- 2023/12/20 00:18
PHST- 2023/07/09 00:00 [received]
PHST- 2023/12/10 00:00 [accepted]
PHST- 2023/12/21 06:42 [medline]
PHST- 2023/12/20 06:42 [pubmed]
PHST- 2023/12/20 00:18 [entrez]
PHST- 2023/12/19 00:00 [pmc-release]
AID - 10.1186/s40001-023-01583-9 [pii]
AID - 1583 [pii]
AID - 10.1186/s40001-023-01583-9 [doi]
PST - epublish
SO  - Eur J Med Res. 2023 Dec 19;28(1):604. doi: 10.1186/s40001-023-01583-9.